267 related articles for article (PubMed ID: 34853079)
1. KAT6A and ENL Form an Epigenetic Transcriptional Control Module to Drive Critical Leukemogenic Gene-Expression Programs.
Yan F; Li J; Milosevic J; Petroni R; Liu S; Shi Z; Yuan S; Reynaga JM; Qi Y; Rico J; Yu S; Liu Y; Rokudai S; Palmisiano N; Meyer SE; Sung PJ; Wan L; Lan F; Garcia BA; Stanger BZ; Sykes DB; Blanco MA
Cancer Discov; 2022 Mar; 12(3):792-811. PubMed ID: 34853079
[TBL] [Abstract][Full Text] [Related]
2. ENL links histone acetylation to oncogenic gene expression in acute myeloid leukaemia.
Wan L; Wen H; Li Y; Lyu J; Xi Y; Hoshii T; Joseph JK; Wang X; Loh YE; Erb MA; Souza AL; Bradner JE; Shen L; Li W; Li H; Allis CD; Armstrong SA; Shi X
Nature; 2017 Mar; 543(7644):265-269. PubMed ID: 28241141
[TBL] [Abstract][Full Text] [Related]
3. Small-Molecule Inhibition of the Acyl-Lysine Reader ENL as a Strategy against Acute Myeloid Leukemia.
Liu Y; Li Q; Alikarami F; Barrett DR; Mahdavi L; Li H; Tang S; Khan TA; Michino M; Hill C; Song L; Yang L; Li Y; Pokharel SP; Stamford AW; Liverton N; Renzetti LM; Taylor S; Watt GF; Ladduwahetty T; Kargman S; Meinke PT; Foley MA; Shi J; Li H; Carroll M; Chen CW; Gardini A; Maillard I; Huggins DJ; Bernt KM; Wan L
Cancer Discov; 2022 Nov; 12(11):2684-2709. PubMed ID: 36053276
[TBL] [Abstract][Full Text] [Related]
4. ENL: structure, function, and roles in hematopoiesis and acute myeloid leukemia.
Zhou J; Ng Y; Chng WJ
Cell Mol Life Sci; 2018 Nov; 75(21):3931-3941. PubMed ID: 30066088
[TBL] [Abstract][Full Text] [Related]
5. Therapy-related Myeloid Leukemia With the Translocation t(8;19)(p11;q13) Leading to a
Panagopoulos I; Andersen K; Ramslien LF; Ikonomou IM; Micci F; Heim S
Anticancer Res; 2021 Apr; 41(4):1753-1760. PubMed ID: 33813379
[TBL] [Abstract][Full Text] [Related]
6. Lysine acetyltransferase 6A maintains CD4
Fu JY; Huang SJ; Wang BL; Yin JH; Chen CY; Xu JB; Chen YL; Xu S; Dong T; Zhou HN; Ma XY; Pu YP; Li H; Yang XJ; Xie LS; Wang ZJ; Luo Q; Shao YX; Ye L; Zong ZR; Wei XD; Xiao WW; Niu ST; Liu YM; Xu HP; Yu CQ; Duan SZ; Zheng LY
Cell Metab; 2024 Mar; 36(3):557-574.e10. PubMed ID: 38237601
[TBL] [Abstract][Full Text] [Related]
7. The key roles of the lysine acetyltransferases KAT6A and KAT6B in physiology and pathology.
Wiesel-Motiuk N; Assaraf YG
Drug Resist Updat; 2020 Dec; 53():100729. PubMed ID: 33130515
[TBL] [Abstract][Full Text] [Related]
8. The leucine twenty homeobox (LEUTX) gene, which lacks a histone acetyltransferase domain, is fused to KAT6A in therapy-related acute myeloid leukemia with t(8;19)(p11;q13).
Chinen Y; Taki T; Tsutsumi Y; Kobayashi S; Matsumoto Y; Sakamoto N; Kuroda J; Horiike S; Nishida K; Ohno H; Uike N; Taniwaki M
Genes Chromosomes Cancer; 2014 Apr; 53(4):299-308. PubMed ID: 24446090
[TBL] [Abstract][Full Text] [Related]
9. KAT6A, a chromatin modifier from the 8p11-p12 amplicon is a candidate oncogene in luminal breast cancer.
Turner-Ivey B; Guest ST; Irish JC; Kappler CS; Garrett-Mayer E; Wilson RC; Ethier SP
Neoplasia; 2014 Aug; 16(8):644-55. PubMed ID: 25220592
[TBL] [Abstract][Full Text] [Related]
10. The histone acetyltransferase KAT6A is recruited to unmethylated CpG islands via a DNA binding winged helix domain.
Weber LM; Jia Y; Stielow B; Gisselbrecht SS; Cao Y; Ren Y; Rohner I; King J; Rothman E; Fischer S; Simon C; Forné I; Nist A; Stiewe T; Bulyk ML; Wang Z; Liefke R
Nucleic Acids Res; 2023 Jan; 51(2):574-594. PubMed ID: 36537216
[TBL] [Abstract][Full Text] [Related]
11. KAT6A mutations in Arboleda-Tham syndrome drive epigenetic regulation of posterior HOXC cluster.
Singh M; Spendlove SJ; Wei A; Bondhus LM; Nava AA; de L Vitorino FN; Amano S; Lee J; Echeverria G; Gomez D; Garcia BA; Arboleda VA
Hum Genet; 2023 Dec; 142(12):1705-1720. PubMed ID: 37861717
[TBL] [Abstract][Full Text] [Related]
12. Loss of Kat2a enhances transcriptional noise and depletes acute myeloid leukemia stem-like cells.
Domingues AF; Kulkarni R; Giotopoulos G; Gupta S; Vinnenberg L; Arede L; Foerner E; Khalili M; Adao RR; Johns A; Tan S; Zeka K; Huntly BJ; Prabakaran S; Pina C
Elife; 2020 Jan; 9():. PubMed ID: 31985402
[TBL] [Abstract][Full Text] [Related]
13. Targeting the Epigenetic Reader ENL Inhibits Super-Enhancer-Driven Oncogenic Transcription and Synergizes with BET Inhibition to Suppress Tumor Progression.
Chen Y; Ying Y; Ma W; Ma H; Shi L; Gao X; Jia M; Li M; Song X; Kong W; Chen W; Zheng X; Muluh TA; Wang X; Wang M; Shu XS
Cancer Res; 2024 Apr; 84(8):1237-1251. PubMed ID: 38241700
[TBL] [Abstract][Full Text] [Related]
14. KAT6A::EP300 fusion in congenital myeloid sarcoma: Yet another novel molecular marker indicating spontaneous remission?: A case report.
Hosahalli Vasanna S; Shah SD; Rohr BR; Roche B; Meyerson H; Pateva I
Medicine (Baltimore); 2023 Jul; 102(30):e34258. PubMed ID: 37505185
[TBL] [Abstract][Full Text] [Related]
15. Inhibitors of histone acetyltransferases KAT6A/B induce senescence and arrest tumour growth.
Baell JB; Leaver DJ; Hermans SJ; Kelly GL; Brennan MS; Downer NL; Nguyen N; Wichmann J; McRae HM; Yang Y; Cleary B; Lagiakos HR; Mieruszynski S; Pacini G; Vanyai HK; Bergamasco MI; May RE; Davey BK; Morgan KJ; Sealey AJ; Wang B; Zamudio N; Wilcox S; Garnham AL; Sheikh BN; Aubrey BJ; Doggett K; Chung MC; de Silva M; Bentley J; Pilling P; Hattarki M; Dolezal O; Dennis ML; Falk H; Ren B; Charman SA; White KL; Rautela J; Newbold A; Hawkins ED; Johnstone RW; Huntington ND; Peat TS; Heath JK; Strasser A; Parker MW; Smyth GK; Street IP; Monahan BJ; Voss AK; Thomas T
Nature; 2018 Aug; 560(7717):253-257. PubMed ID: 30069049
[TBL] [Abstract][Full Text] [Related]
16. Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia.
Kühn MW; Song E; Feng Z; Sinha A; Chen CW; Deshpande AJ; Cusan M; Farnoud N; Mupo A; Grove C; Koche R; Bradner JE; de Stanchina E; Vassiliou GS; Hoshii T; Armstrong SA
Cancer Discov; 2016 Oct; 6(10):1166-1181. PubMed ID: 27535106
[TBL] [Abstract][Full Text] [Related]
17. The epigenetic regulators CBP and p300 facilitate leukemogenesis and represent therapeutic targets in acute myeloid leukemia.
Giotopoulos G; Chan WI; Horton SJ; Ruau D; Gallipoli P; Fowler A; Crawley C; Papaemmanuil E; Campbell PJ; Göttgens B; Van Deursen JM; Cole PA; Huntly BJ
Oncogene; 2016 Jan; 35(3):279-89. PubMed ID: 25893291
[TBL] [Abstract][Full Text] [Related]
18. Pantothenate and L-Carnitine Supplementation Improves Pathological Alterations in Cellular Models of KAT6A Syndrome.
Munuera-Cabeza M; Álvarez-Córdoba M; Suárez-Rivero JM; Povea-Cabello S; Villalón-García I; Talaverón-Rey M; Suárez-Carrillo A; Reche-López D; Cilleros-Holgado P; Piñero-Pérez R; Sánchez-Alcázar JA
Genes (Basel); 2022 Dec; 13(12):. PubMed ID: 36553567
[TBL] [Abstract][Full Text] [Related]
19. Acute myeloid leukemia with t(8;16)(p11.2;p13.3)/KAT6A-CREBBP in adults.
Xie W; Hu S; Xu J; Chen Z; Medeiros LJ; Tang G
Ann Hematol; 2019 May; 98(5):1149-1157. PubMed ID: 30759270
[TBL] [Abstract][Full Text] [Related]
20. KAT6A is associated with sorafenib resistance and contributes to progression of hepatocellular carcinoma by targeting YAP.
Jin Y; Yang R; Ding J; Zhu F; Zhu C; Xu Q; Cai J
Biochem Biophys Res Commun; 2021 Dec; 585():185-190. PubMed ID: 34808502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
